Company profile: Skyhawk Therapeutics
1.1 - Company Overview
Company description
- Provider of small molecule therapeutics and RNA-targeting platforms that correct RNA expression. Offers SKYSTAR for RNA target assessment and prioritization; SKYLIBRARY of RNA-targeting compounds; SKYSEQ multiplex screening for testing multiple RNA targets; and SKYAI machine-learning tools for advancing RNA splicing modulators. Pipeline includes SKY-0515, a small molecule RNA splicing modifier for Huntington’s disease in clinical trials.
Products and services
- SKY-0515: A clinical-stage small molecule RNA splicing modifier targeting Huntington's Disease, engineered to correct RNA expression by modulating splicing, with ongoing clinical trials
- SKYSTAR®: A multimodal platform that assesses RNA targets by merging diverse datasets to prioritize targets for drug development, enabling rigorous target triage
- SKYAI™: An AI-driven machine learning toolset integrating data from multiple sources to advance development of RNA splicing modulators
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Skyhawk Therapeutics
Biogazelle
HQ: Belgium
Website
- Description: Provider of genomic testing solutions and expert laboratory services in nucleic acid quantification—including gene expression, mutation, and copy number analysis—and antisense oligonucleotide screening to support development of diagnostics and therapeutics. Offers customized workflows for clinically relevant samples, from liquid biopsies to fixed tissues.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biogazelle company profile →
Foghorn Therapeutics
HQ: United States
Website
- Description: Provider of targeted therapies leveraging its Gene Traffic Control platform to modulate the chromatin regulatory system, including FHD-286, an enzymatic BRG1/BRM inhibitor for AML and MDS; a selective BRM inhibitor and degrader for cancers with BRG1 mutations; and an ARID1B degrader for cancers with ARID1A mutations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Foghorn Therapeutics company profile →
4D Molecular Therapeutics
HQ: United States
Website
- Description: Provider of transformative gene therapeutic products enabled by a Therapeutic Vector Evolution Platform using directed evolution to create customized viral vectors for targeted delivery. Offers R100 for retinal diseases, A101 for aerosol lung delivery, and C102 for intravenous heart muscle delivery, plus a product design & development engine and in-house GMP manufacturing and IND-enabling technical operations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 4D Molecular Therapeutics company profile →
Laronde
HQ: United States
Website
- Description: Provider of an eRNA-based therapeutic platform, offering Endless RNA to program protein expression for therapeutic use; proprietary Natural NanoParticle technology to deliver biomolecules into human cells, enabling diverse administration routes and re-dosing; and AI-driven drug development using proprietary algorithms for rapid RNA medicine design.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Laronde company profile →
Egen
HQ: United States
Website
- Description: Provider of safe, efficient delivery systems for the manufacture of nucleic acid and anti-cancer drugs and for creating products to treat human diseases, offering synthetic biocompatible delivery vehicles to deliver therapeutic genes, inhibitory RNA (siRNA & shRNA), and small molecules.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Egen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Skyhawk Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Skyhawk Therapeutics
2.2 - Growth funds investing in similar companies to Skyhawk Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Skyhawk Therapeutics
4.2 - Public trading comparable groups for Skyhawk Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →